ArriVent BioPharma, Inc. Common Stock Total Liabilities
ArriVent BioPharma, Inc. Common Stock total liabilities. Based on the latest financial reports, ArriVent BioPharma, Inc. Common Stock (AVBP) has total liabilities worth $27.88 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of ArriVent BioPharma, Inc. Common Stock to evaluate the company's liquid asset resilience ratio.
Total Liabilities of ArriVent BioPharma, Inc. Common Stock (2021–2025)
Total liabilities of ArriVent BioPharma, Inc. Common Stock from 2021 to 2025. This chart illustrates how ArriVent BioPharma, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore how much of ArriVent BioPharma, Inc. Common Stock's assets are long-term investments to see how much of total assets are deployed in long-term investments.
ArriVent BioPharma, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of ArriVent BioPharma, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hebei Huijin Electromechanical Co Ltd
SHE:300368
|
China | CN¥280.87 Million |
|
Guangdong Silvere Sci and Tech
SHE:300221
|
China | CN¥893.52 Million |
|
Africa Israel Residences Ltd
TA:AFRE
|
Israel | ILA3.29 Billion |
|
MN Holdings Berhad
KLSE:0245
|
Malaysia | RM322.32 Million |
|
Jiangyin Haida Rubber and Plastic Co Ltd Class A
SHE:300320
|
China | CN¥1.08 Billion |
|
Sichuan Huiyu Pharmaceutical Co Ltd
SHG:688553
|
China | CN¥1.16 Billion |
|
LSI Industries Inc
NASDAQ:LYTS
|
USA | $148.21 Million |
|
Huarui Electrical Appliance Co Ltd
SHE:300626
|
China | CN¥356.45 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down ArriVent BioPharma, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of ArriVent BioPharma, Inc. Common Stock.
Liquidity & Leverage Metrics
ArriVent BioPharma, Inc. Common Stock Total Liabilities Ratios Explained
ArriVent BioPharma, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ArriVent BioPharma, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ArriVent BioPharma, Inc. Common Stock (2021–2025)
The table below shows the annual total liabilities of ArriVent BioPharma, Inc. Common Stock from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $25.95 Million | +50.08% |
| 2024-09-30 | $17.29 Million | +46.50% |
| 2023-09-30 | $11.80 Million | +40.97% |
| 2022-09-30 | $8.37 Million | +360.45% |
| 2021-09-30 | $1.82 Million | -- |
About ArriVent BioPharma, Inc. Common Stock
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutati… Read more